Documents
Study protocol
Initial protocol

ER-9489_AZ DAHLIA_Pharmacoepidemiological study protocol_v10_20150224_final_signed

English (1 MB - PDF)View document
Updated protocol

ER-9489_AZ DAHLIA_Amendment to pharmacoepidemiological study protocol_v21_20170503_signed

First published: 22/02/2024
English (870 KB - PDF)View document
Study results
Study results

ER-9489-DAHLIA_Report synopsis_V1.0_20171114_signed

English (1.28 MB - PDF)View document
Study report
Other information
Study, other information

ER-9489_Annex5_DoIForm_Johan Eriksson_signed

English (161.76 KB - PDF)View document

ER-9489_AZ DAHLIA_Pharmacoepidemiological study protocol_v20_20150827_signed

English (1.53 MB - PDF)View document

ER-9489_AZ DAHLIA_Pharmacoepidemiological study protocol_v21_20160607_signed

English (686.2 KB - PDF)View document
ENCePP Seal
This study has been awarded the ENCePP seal
ENCePP Seal documents
Conflicts of interest of investigators

ER-9489_Annex5_DoIForm_20150331_signed_EPID

English (1.45 MB - PDF)View document

ER-9489_Annex5_DoIForm_20150408_signed_clinical expert and sponsor

English (1.24 MB - PDF)View document

ER-9489_Annex5_DoIForm_20170703_signed

English (3.59 MB - PDF)View document
Composition of steering group and observers

Composition of steering committee_20170503

English (34.04 KB - PDF)View document

EUPAS8202-8701

English (53.89 KB - PDF)View document